Handelsavisen
prelaunch
Companies Healthcare KPTI.BO
KP
KPTI.BO BSE (India) Diversified Pharmaceuticals

KPT Industries Ltd

$476,20
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,57 %
Op margin
13,9 %
ROE
6,6 %
Net margin
9,3 %
Debt / equity
0,67
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

KPT Industries Ltd is an industrial machinery and equipment manufacturer that generates revenue through the production and sale of industrial goods.

Business. KPT Industries Ltd (KPTI.BO) is an Indian industrial goods company engaged in the manufacturing and sale of industrial machinery and equipment. The firm operates within the Industrial Machinery & Equipment industry, generating revenue primarily through product sales. Headquartered in India, the company is listed on the Bombay Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY7 analysts
6 buy1 hold0 sell
Avg 12m price target13,40

Analyst recommendations

7 analysts · consensus Buy
Buy6
Hold1
Sell0
12-month price target
13,40
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
7 analysts · indicative
Ownership
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability
6,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning KPTI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to KPTI.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    KPT Industries Ltd (KPTI.BO) is an Indian industrial goods company engaged in the manufacturing and sale of industrial machinery and equipment. The firm operates within the Industrial Machinery & Equipment industry, generating revenue primarily through product sales. Headquartered in India, the company is listed on the Bombay Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Pharmaceuticals
    AI synthesis
    GENERATED

    KPT Industries Ltd maintains a debt-to-equity ratio of 0.67, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium risk, with a current ratio of 1.61, suggesting it can cover short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    Profitability metrics show a return on equity (ROE) of 6.59% and a return on assets (ROA) of 3.03%. These figures are below the industry median for ROE and ROA, indicating that KPT Industries Ltd is underperforming its peers in terms of capital efficiency and asset utilization.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and sector-specific risks. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution.

    Looking ahead, the company's growth trajectory is constrained by a negative capital expenditure of INR 67.18 million, suggesting a reduction in investment in long-term assets. This may indicate a strategic shift or financial constraints. The outlook for the current fiscal year shows a modest revenue growth, but the next fiscal year is expected to see a decline in revenue, based on the capital expenditure trend and liquidity position.

    Risk factors include a medium liquidity risk and a low dilution risk. The company's liquidity risk is driven by its negative net cash position and moderate debt levels. The dilution risk is low, as there is no indication of recent or planned share issuance that would significantly dilute existing shareholders.

    Recent events include the filing of the latest financial report, which disclosed the negative net cash position and reduced capital expenditure. No significant earnings call transcripts or regulatory filings have been reported in the last quarter, limiting the availability of qualitative insights into the company's strategic direction.

    Key takeaways
    • KPT Industries Ltd has a moderate debt-to-equity ratio but faces liquidity constraints due to a negative net cash position.
    • The company's ROE and ROA are below industry medians, indicating underperformance in capital efficiency and asset utilization.
    • Revenue and geographic diversification data are not disclosed, increasing exposure to regional and sector-specific risks.
    • Capital expenditure is negative, suggesting a reduction in investment in long-term assets and potential financial constraints.
    • The company's liquidity risk is medium, and dilution risk is low, with no recent or planned share issuance.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Free cash flow surged 63% year-over-year to INR 131.4 million, demonstrating strong cash generation capabilities.

    Net income grew 15.5% year-over-year, outpacing the 9.5% revenue growth rate.

    Return on equity of 6.6% exceeds the cohort median of 3.6% for industrial machinery firms.

    Cash conversion ratio of 1.26 is above the cohort median of 0.95.

    BEAR CASE · 4

    Credit risk is flagged as high, indicating significant potential for financial distress or default.

    Debt-to-equity ratio of 0.67 places the company in the bottom quartile of its peer cohort.

    Liquidity risk is assessed as medium, suggesting potential challenges in meeting short-term obligations.

    Capex to revenue ratio of -17.1% is in the bottom quartile, indicating heavy capital intensity.

    In focus — financials by report

    Valuation FY

    Market price
    $476,20
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $553.6M
    Net cash
    -$349.4M
    Current ratio
    1.6
    Debt / equity
    0.7
    ROA
    3.0%
    ROE
    6.6%
    Cash conversion
    126.0%
    CapEx / revenue
    -17.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Pharmaceuticals1 042,4B node revenueMCK 38,7%COR 30,8%CAH 21,4%DB 3,4%REGN 1,4%BIIB 0,9%ZTS 0,9%GRFS 0,8%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)KPTI 0,0% · rank #18 of 40

    Business relationships

    Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries2
    EX21:648d60df70e5EX21:648d60df70e5Subsidiarie97%
    EX21:e90889f1b0ccEX21:e90889f1b0ccSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs KPTI · multiples and returns
    MC
    MCK
    Mckesson Corp
    $827,14
    102,6B USD
    P/E
    21,2x
    vs self
    Div yield
    0,4 %
    vs self
    ROE
    -219,2 %
    -286,2 vs self
    CO
    COR
    Cencora Inc
    $308,37
    60,2B USD
    P/E
    36,4x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    45,7 %
    -21,2 vs self
    CA
    CAH
    Cardinal Health Inc
    $235,60
    57,0B USD
    P/E
    36,7x
    vs self
    Div yield
    0,9 %
    vs self
    ROE
    -55,9 %
    -122,8 vs self
    DB
    DB
    DB.V
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    RE
    REGN
    REGENERON PHARMACEUTICALS, INC.
    $757,99
    81,0B USD
    P/E
    15,5x
    vs self
    Div yield
    vs self
    ROE
    14,2 %
    -52,7 vs self
    BI
    BIIB
    BIOGEN INC.
    $201,74
    29,6B USD
    P/E
    21,3x
    vs self
    Div yield
    vs self
    ROE
    7,5 %
    -59,4 vs self
    ZT
    ZTS
    Zoetis Inc
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GR
    GRFS
    Grifols SA
    $7,86
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -4,23
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    7
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$7,00
    Mean$13,40
    Median$15,00
    High$16,00
    Spot$476,20
    −97.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,9 %Above median
    Net Margin9,3 %Above median
    ROE6,6 %Above median
    Capex / Rev-17,1 %Bottom quartile
    D/E0,67Bottom quartile
    Cash Conv1,26Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • KPT Industries Ltd Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$5M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$4M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$4M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Richard A. PaulsonPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 15 sellsnet -$346K13 insiders · last 365d
    • Schor ChenDirector · Common StockOther 15 508 · 2026-05-21
    • Oliger Christy J.Director · Common StockOther 15 508 · 2026-05-21
    • PAKIANATHAN DEEPIKADirector · Common StockOther 15 508 · 2026-05-21
    • Su ZhenDirector · Common StockOther 15 508 · 2026-05-21
    • BOHLIN GAREN GDirector · Common StockOther 15 508 · 2026-05-21
    • Greene Barry EDirector · Common StockOther 15 508 · 2026-05-21
    • Rangwala ReshmaEVP & Chief Medical Officer · Common StockSold 408 @ $9,50$4K · 2026-05-14
    • Abate KristinChief Accounting Officer · Common StockSold 53 @ $9,50$504 · 2026-05-14
    • Poulton StuartEVP, Chief Development Officer · Common StockSold 403 @ $9,50$4K · 2026-05-14
    • Paulson Richard A.Director, President and CEO · Common StockSold 2 203 @ $9,50$21K · 2026-05-14
    • Cheng Sohanya RoshanEVP & Chief Commercial Officer · Common StockSold 324 @ $9,50$3K · 2026-05-14
    • Mano MichaelEVP, CLO&Secretary · Common StockSold 266 @ $9,50$3K · 2026-05-14
    • Poulton StuartEVP, Chief Development Officer · Common StockOther 896 · 2026-05-13
    • Rangwala ReshmaEVP & Chief Medical Officer · Common StockOther 947 · 2026-05-13
    • Cheng Sohanya RoshanEVP & Chief Commercial Officer · Common StockOther 947 · 2026-05-13
    • Abate KristinChief Accounting Officer · Common StockOther 121 · 2026-05-13
    • Paulson Richard A.Director, President and CEO · Common StockOther 4 920 · 2026-05-13
    • Mano MichaelEVP, CLO&Secretary · Common StockOther 700 · 2026-05-13
    • Rangwala ReshmaEVP & Chief Medical Officer · Common StockSold 449 @ $8,94$4K · 2026-04-21
    • Abate KristinChief Accounting Officer · Common StockSold 559 @ $9,41$5K · 2026-03-02
    • Mano MichaelEVP, CLO&Secretary · Common StockSold 3 526 @ $9,41$33K · 2026-03-02
    • Cheng Sohanya RoshanEVP & Chief Commercial Officer · Common StockSold 4 604 @ $9,41$43K · 2026-03-02
    • Rangwala ReshmaEVP & Chief Medical Officer · Common StockSold 5 066 @ $9,41$48K · 2026-03-02
    • Paulson Richard A.Director, President and CEO · Common StockSold 12 361 @ $9,41$116K · 2026-03-02
    • Poulton StuartEVP, Chief Development Officer · Common StockSold 5 101 @ $9,41$48K · 2026-03-02

    Short positioning

    6.3Mshares short-4.1% vs prior
    17.13days to cover
    34.7%short of daily vol
    1.4Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    KPTI.BOCanonical
    BSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    KPTIEX21:648EX21:e90Diversified Ph
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 14.5%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -34.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -57.5%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 24.1%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 40.9%Derived (calculated)
    • Net margin (FY 2025-12-31): -134.2%Derived (calculated)
    • Return on equity (FY 2025-12-31): 66.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): -180.8%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.12xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): -1.37xDerived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 0.6%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -156.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -3.1%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -90.5%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -28.1%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -12.3%Derived (calculated)
    • Total liabilities (annual): USD 401.34MSEC XBRL filing
    • Cash & equivalents (annual): USD 60.54MSEC XBRL filing
    • Capex (annual): USD 0SEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -18SEC XBRL filing
    • Net income (annual): USD -196.04MSEC XBRL filing
    • Total operating expenses (annual): USD 236.77MSEC XBRL filing
    • Current assets (annual): USD 103.15MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-05-28FILING8-K filing →
    2026-05-21 00:00 UTCINSIDER18 insider transactions — 2026-05
    2026-05-21INSIDERSchor Chen transacted 15.5k sh — Director
    2026-05-21INSIDEROliger Christy J. transacted 15.5k sh — Director
    2026-05-21INSIDERPAKIANATHAN DEEPIKA transacted 15.5k sh — Director
    2026-05-21INSIDERSu Zhen transacted 15.5k sh — Director
    2026-05-21INSIDERBOHLIN GAREN G transacted 15.5k sh — Director
    2026-05-21INSIDERGreene Barry E transacted 15.5k sh — Director
    2026-05-14FILING10-Q filing →
    2026-05-14FILING8-K filing →
    2026-05-14INSIDERRangwala Reshma sold 408 sh — EVP & Chief Medical Officer ~$4k
    2026-05-14INSIDERAbate Kristin sold 53 sh — Chief Accounting Officer ~$1k
    2026-05-14INSIDERPoulton Stuart sold 403 sh — EVP, Chief Development Officer ~$4k
    2026-05-14INSIDERPaulson Richard A. sold 2.2k sh — Director, President and CEO ~$21k
    2026-05-14INSIDERCheng Sohanya Roshan sold 324 sh — EVP & Chief Commercial Officer ~$3k
    2026-05-14INSIDERMano Michael sold 266 sh — EVP, CLO&Secretary ~$3k
    2026-05-13INSIDERPoulton Stuart transacted 896 sh — EVP, Chief Development Officer
    2026-05-13INSIDERRangwala Reshma transacted 947 sh — EVP & Chief Medical Officer
    2026-05-13INSIDERCheng Sohanya Roshan transacted 947 sh — EVP & Chief Commercial Officer
    2026-05-13INSIDERAbate Kristin transacted 121 sh — Chief Accounting Officer
    2026-05-13INSIDERPaulson Richard A. transacted 4.9k sh — Director, President and CEO
    2026-05-13INSIDERMano Michael transacted 700 sh — EVP, CLO&Secretary
    2026-04-21 00:00 UTCINSIDER1 insider transaction — 2026-04
    2026-04-21INSIDERRangwala Reshma sold 449 sh — EVP & Chief Medical Officer ~$4k
    2026-04-13FILINGDEF 14A filing →
    2026-03-27FILING8-K filing →
    2026-03-24FILING8-K filing →
    2026-03-03FILING8-K filing →
    2026-03-02 00:00 UTCINSIDER6 insider transactions — 2026-03 · net sell $294k
    2026-03-02INSIDERAbate Kristin sold 559 sh — Chief Accounting Officer ~$5k
    Showing the 40 most recent of 52 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage